Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ASSESSMENT OF HORMONE-REFRACTORY PROSTATE-CANCER
Autore:
NEWLING D; FOSSA SD; ANDERSSON L; ABRAHAMSSON PA; ASO Y; EISENBERGER MA; KHOURY S; KOZLOWSKI JS; KELLY K; SCHER H; HARTLEYASP B;
Indirizzi:
FREE UNIV AMSTERDAM,ACAD HOSP,DEPT UROL NL-1007 MB AMSTERDAM NETHERLANDS NORWEGIAN RADIUM HOSP,DEPT ONCOL OSLO NORWAY KAROLINSKA HOSP,WORLD HLTH ORG,COLLABORATING CTR UROL TUMORS S-10401 STOCKHOLM SWEDEN UNIV LUND HOSP,DEPT UROL S-22185 LUND SWEDEN FUJIEDA MUNICIPAL GEN HOSP TOKYO JAPAN JOHNS HOPKINS UNIV,SCH MED,JOHNS HOPKINS ONCOL CTR BALTIMORE MD 21205 HOP PITIE,UROL CLIN F-75651 PARIS FRANCE NORTHWESTERN UNIV,SCH MED,DEPT UROL CHICAGO IL 60611 MEM SLOAN KETTERING CANC CTR,DEPT MED NEW YORK NY 10021 PHARMACIA UPJOHN AB LUND SWEDEN
Titolo Testata:
Urology
fascicolo: 4A, volume: 49, anno: 1997, supplemento:, S
pagine: 46 - 53
SICI:
0090-4295(1997)49:4A<46:AOHP>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
FLUTAMIDE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
D. Newling et al., "ASSESSMENT OF HORMONE-REFRACTORY PROSTATE-CANCER", Urology, 49(4A), 1997, pp. 46-53

Abstract

Objectives. To define guidelines for the assessment of treatment in patients with hormone-refractory prostate cancer (HRPC). Methods. In the light of modern research, and taking new treatment options into account, the Committee essays to specify different categories of patients entering clinical trials, and to define response criteria and those endpoints that are relevant in phase III studies and in short-term follow-up. Results. HRPC comprises a range of disease states with varying responsiveness to therapy and length of survival. Patients with progression as evaluated by increasing prostate-specific antigen (PSA) valuesalone have a more favorable prognosis than those presenting with increasing tumor spread. In the assessment of these patients, the modes ofprevious therapy and the kind of tumor progression must be taken intoaccount. The benefit of treatment of HRPC is often modest. While duration of survival remains the main and ultimate endpoint, the means of measuring short-term responsiveness to therapy are limited, A minorityof patients have measurable tumor lesions. Decrease of PSA or other biochemical turner markers may indicate depression of the tumor activity, but is not always associated with prolongation of survival. A variety of new treatments in HRPC are being investigated. They affect measurable tumor parameters in different ways. Conclusions. When a new agent is to be tested, it is important to measure all possible parameters before deciding which particular ones are appropriate for future investigations of this agent, In symptomatic patients, evaluation of subjective parameters, for example, relief of pain or improvement of performance status, is often the most reliable measure of treatment effect. However, these parameters should be clearly defined. (C) 1997 by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 22:29:30